Compare Stocks: TPST, CELU, ELTX, and INMB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.25 -6.0%	$1.28	$0.56 ▼ $2.55	$40.56M	0.77	1.35 million shs	63,835 shs
ELTX Elicio Therapeutics	$1.56 -12.4%	$2.35	$1.55 ▼ $16.00	$42.26M	1.32	666,203 shs	333,447 shs
INMB INmune Bio	$1.57 -4.8%	$2.13	$1.09 ▼ $2.60	$43.57M	0.89	499,573 shs	196,169 shs
TPST Tempest Therapeutics	$0.62 -1.7%	$0.94	$0.62 ▼ $11.15	$10.54M	-1.73	947,907 shs	67,110 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	+1.53%	-8.90%	+7.26%	+70.45%	-38.71%
ELTX Elicio Therapeutics	-0.56%	-1.66%	-10.55%	-42.77%	-83.05%
INMB INmune Bio	+3.12%	-9.84%	-26.99%	-13.16%	-14.51%
TPST Tempest Therapeutics	-0.03%	-17.53%	-16.45%	-34.27%	-94.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.25 -6.0%	$1.28	$0.56 ▼ $2.55	$40.56M	0.77	1.35 million shs	63,835 shs
ELTX Elicio Therapeutics	$1.56 -12.4%	$2.35	$1.55 ▼ $16.00	$42.26M	1.32	666,203 shs	333,447 shs
INMB INmune Bio	$1.57 -4.8%	$2.13	$1.09 ▼ $2.60	$43.57M	0.89	499,573 shs	196,169 shs
TPST Tempest Therapeutics	$0.62 -1.7%	$0.94	$0.62 ▼ $11.15	$10.54M	-1.73	947,907 shs	67,110 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	+1.53%	-8.90%	+7.26%	+70.45%	-38.71%
ELTX Elicio Therapeutics	-0.56%	-1.66%	-10.55%	-42.77%	-83.05%
INMB INmune Bio	+3.12%	-9.84%	-26.99%	-13.16%	-14.51%
TPST Tempest Therapeutics	-0.03%	-17.53%	-16.45%	-34.27%	-94.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	1.00	Sell	N/A	N/A
ELTX Elicio Therapeutics	2.50	Moderate Buy	$15.00	864.63% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
TPST Tempest Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest TPST, CELU, ELTX, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	TPST Tempest Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/24/2026	ELTX Elicio Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$8.00
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.52	N/A	N/A	($1.32) per share	-0.94
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
INMB INmune Bio	$50K	866.36	N/A	N/A	$0.88 per share	1.77
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$2.73	N/A	N/A	N/A	-374.87%	N/A	-64.45%	11/13/2026 (Estimated)
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
TPST Tempest Therapeutics	-$26.26M	-$4.28	N/A	N/A	N/A	N/A	-576.56%	-134.99%	11/4/2026 (Estimated)

Latest TPST, CELU, ELTX, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ELTX Elicio Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	TPST Tempest Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	INMB INmune Bio	-$0.1467	N/A	N/A	N/A	$1.88 million	N/A
9/29/2026	Q1 2026	CELU Celularity	N/A	$0.02	N/A	$0.02	N/A	$3.85 million
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A
8/13/2026	Q2 2026	TPST Tempest Therapeutics	-$0.30	-$0.34	-$0.04	-$0.34	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.09	0.08
ELTX Elicio Therapeutics	1.20	2.77	2.77
INMB INmune Bio	N/A	4.04	4.04
TPST Tempest Therapeutics	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
ELTX Elicio Therapeutics	35.03%
INMB INmune Bio	12.72%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
ELTX Elicio Therapeutics	50.90%
INMB INmune Bio	21.40%
TPST Tempest Therapeutics	36.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	115	32.45 million	26.84 million	Optionable
ELTX Elicio Therapeutics	N/A	27.09 million	13.30 million	Not Optionable
INMB INmune Bio	21	27.75 million	21.82 million	Optionable
TPST Tempest Therapeutics	4	16.89 million	10.78 million	No Data

TPST, CELU, ELTX, and INMB Headlines

Recent News About These Companies

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

October 14 at 8:00 AM | globenewswire.com

Tempest Therapeutics (NASDAQ:TPST) Upgraded to Sell at Wall Street Zen

October 10, 2026 | americanbankingnews.com

Tempest Therapeutics consensus price target decreased by 36.36% to $7.14

October 2, 2026 | msn.com

Tempest Therapeutics names Nancy Freda-Smith to its board

September 23, 2026 | streetinsider.com

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

September 23, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

September 16, 2026 | finanznachrichten.de

Tempest Stock Exploded on a CAR-T Option Most Investors Had Never Heard Of

September 16, 2026 | moneymorning.comM

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

September 16, 2026 | benzinga.com

Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%

September 16, 2026 | rttnews.com

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

September 16, 2026 | streetinsider.com

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

September 15, 2026 | finance.yahoo.com

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

September 15, 2026 | globenewswire.com

Tempest Therapeutics announces $2.5M private placement

September 11, 2026 | msn.com

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

September 11, 2026 | globenewswire.com

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

August 13, 2026 | quiverquant.comQ

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | finanznachrichten.de

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

July 21, 2026 | quiverquant.comQ

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, CELU, ELTX, and INMB Company Descriptions

Celularity NASDAQ:CELU

$1.25 -0.08 (-6.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.00 (+0.40%)

As of 06:03 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Elicio Therapeutics NASDAQ:ELTX

$1.56 -0.22 (-12.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.62 +0.06 (+3.91%)

As of 04:45 PM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

INmune Bio NASDAQ:INMB

$1.57 -0.08 (-4.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.00 (+0.32%)

As of 04:28 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Tempest Therapeutics NASDAQ:TPST

$0.62 -0.01 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$0.63 +0.00 (+0.45%)

As of 05:58 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TPST, CELU, ELTX, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TPST, CELU, ELTX, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TPST, CELU, ELTX, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, CELU, ELTX, and INMB Company Descriptions

Celularity NASDAQ:CELU

Elicio Therapeutics NASDAQ:ELTX

INmune Bio NASDAQ:INMB

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TPST, CELU, ELTX, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TPST, CELU, ELTX, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TPST, CELU, ELTX, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, CELU, ELTX, and INMB Company Descriptions

Celularity NASDAQ:CELU

Elicio Therapeutics NASDAQ:ELTX

INmune Bio NASDAQ:INMB

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools